Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Total Non-Current Liabilities (2016 - 2023)

Vistagen Therapeutics (VTGN) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $3.6 million as the latest value for Q3 2023.

  • Quarterly Total Non-Current Liabilities fell 27.92% to $3.6 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Sep 2023, down 27.92% year-over-year, with the annual reading at $4.4 million for FY2023, 6.7% up from the prior year.
  • Total Non-Current Liabilities hit $3.6 million in Q3 2023 for Vistagen Therapeutics, down from $4.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $12.7 million in Q3 2020 to a low of $3.6 million in Q3 2023.
  • Historically, Total Non-Current Liabilities has averaged $7.7 million across 5 years, with a median of $8.1 million in 2019.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 153.39% in 2019 and later tumbled 68.83% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $8.5 million in 2019, then soared by 47.01% to $12.5 million in 2020, then tumbled by 66.85% to $4.1 million in 2021, then increased by 14.73% to $4.7 million in 2022, then dropped by 23.3% to $3.6 million in 2023.
  • Business Quant data shows Total Non-Current Liabilities for VTGN at $3.6 million in Q3 2023, $4.1 million in Q2 2023, and $4.4 million in Q1 2023.